The 2024 ASH Annual Meeting sparked a flurry of online discussions among hematology HCPs on X.com. Utilizing AI-powered analysis of 5,000 posts surrounding the event, StratInt has published a new white paper: “Social Media Trends & Outlook: ASH 2024 HCP Conversations.”
This report, powered by Sipherio, an AI-driven analytics platform, highlights several notable trends and key voices:
- CAR T-cell therapy dominated the discussions, with HCPs exploring its expansion into solid tumors and the development of next-generation technologies.
- Minimal residual disease (MRD) testing and genomic complexity in multiple myeloma also emerged as crucial areas of focus.
- The integration of AI and electronic Patient Reported Outcomes (ePROs) to personalize treatment and address healthcare disparities was a recurring theme.
- Preliminary results from the iMMAGINE-1 study drew significant attention to the promise of anitocabtagene-autoleucel (anito-cel) in relapsed/refractory multiple myeloma (RRMM), while potential changes to medical research funding began to emerge as a topic of concern.
- Drs. Rahul Banerjee, Ajay Major, Samer Al’Hadidi, and John Leonard stood out as KOLs, driving discussions on CAR T-cell therapy, MRD testing, and genomic complexity.
Ready to dive deeper and see what trends and voices Sipherio anticipates at ASCO 2025 and hematology social conversations in general? Download the full white paper below.
